What is Helius Medical Technologies Median PS Value?
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Helius Medical Technologies's Median PS Value or its related term are showing as below:
HSDT's Price-to-Median-PS-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.79 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Helius Medical Technologies Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Helius Medical Technologies's Median PS Value
For the Medical Devices subindustry, Helius Medical Technologies's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Helius Medical Technologies's Price-to-Median-PS-Value Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Helius Medical Technologies's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Helius Medical Technologies's Price-to-Median-PS-Value falls into.
Helius Medical Technologies Median PS Value Calculation
10-Year Median PS Ratio is 0.
Helius Medical Technologies's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.054.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Helius Medical Technologies (NAS:HSDT) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Helius Medical Technologies's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
4.00
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Helius Medical Technologies Median PS Value Related Terms
Thank you for viewing the detailed overview of Helius Medical Technologies's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Helius Medical Technologies (Helius Medical Technologies) Business Description
Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS), is authorized for sale in Canada as a class II, non-implantable medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HSDT has been successfully added to your 